The relative strength index (RSI) is a momentum indicator developed by noted technical analyst Welles Wilder which compares the magnitude of recent gains and losses over a specified time period to measure speed and change of price movements of a security. It is primarily used to attempt to identify overbought or oversold conditions in the trading of an asset.
Calculation: Relative Strength Index (RSI):
1) RSI = 100 - 100 / (1 + RS);
2) RS = Average Gain / Average Loss;
PROFILE: Opthea (OPT.AX)
Stock Exchange: ASXAbout Opthea (ASX:OPT):
Ticker Codes: | OPT.AX | ASX:OPT |
Opthea Limited develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) C and D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3, which is in Phase 1/2A clinical trial for the treatment of back of the eye diseases, such as wet age-related macular degeneration that is the cause of blindness in elderly and diabetic populations. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited is based in South Yarra, Australia.